AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (AGIO)

Q: What does CUSIP 00847X104 represent in this 13F holders report?

CUSIP 00847X104 is the security identifier for AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share in Q2 2024?

203 institutional investors reported AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share for Q2 2024. Use the holders table for investor-level position and value details.

CUSIP: 00847X104

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class: Equity / Common Stock, Par Value $0.001 per share
Shares outstanding: 59,431,072
Total 13F shares: 58,132,966
Share change: -3,758,427
Total reported value: $2,506,935,894
Put/Call ratio: 107%
Price per share: $43.12
Number of holders: 203
Value change: -$125,225,015
Number of buys: 95
Number of sells: 108

Quarterly Holders Quick Answers

What is CUSIP 00847X104?
CUSIP 00847X104 identifies AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2024
Previous quarter: Q1 2024

Recent filing periods for CUSIP 00847X104:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	9.4%	5,590,602	$163,469,202	—	31 Mar 2024	13F
VANGUARD GROUP INC	13F	Company	9.4%	5,572,021	$162,925,894	—	31 Mar 2024	13F
BlackRock Finance, Inc.	13F	Company	7.8%	4,658,095	$136,202,699	—	31 Mar 2024	13F
Bellevue Group AG	13F	Company	6.7%	4,006,000	$117,135,440	—	31 Mar 2024	13F
STATE STREET CORP	13F	Company	5.3%	3,138,197	$91,760,880	—	31 Mar 2024	13F
ARMISTICE CAPITAL, LLC	13F	Company	5%	2,964,000	$86,667,360	—	31 Mar 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	4.3%	2,578,558	$75,397,035	—	31 Mar 2024	13F
JPMORGAN CHASE & CO	13F	Company	4.2%	2,472,690	$72,301,455	—	31 Mar 2024	13F
Erste Asset Management GmbH	13F	Company	3.8%	2,279,900	$66,651,688	—	31 Mar 2024	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	3.4%	2,012,993	$58,861,000	—	31 Mar 2024	13F
MACQUARIE GROUP LTD	13F	Company	3.3%	1,959,657	$57,300,000	—	31 Mar 2024	13F
Rock Springs Capital Management LP	13F	Company	3%	1,764,505	$51,594,126	—	31 Mar 2024	13F
ArrowMark Colorado Holdings LLC	13F	Company	2.6%	1,519,163	$44,420,326	—	31 Mar 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	2.2%	1,282,915	$37,517,545	—	31 Mar 2024	13F
MORGAN STANLEY	13F	Company	2%	1,180,326	$34,512,733	—	31 Mar 2024	13F
BNP Paribas Asset Management Holding S.A.	13F	Company	1.9%	1,108,613	$32,416,000	—	31 Mar 2024	13F
Pictet Asset Management Holding SA	13F	Company	1.7%	1,005,626	$29,344,565	—	31 Mar 2024	13F
CITADEL ADVISORS LLC	13F	Company	1.7%	1,002,461	$29,311,960	—	31 Mar 2024	13F
T. Rowe Price Investment Management, Inc.	13F	Company	1.6%	928,596	$27,153,000	—	31 Mar 2024	13F
Fisher Asset Management, LLC	13F	Company	1.2%	707,342	$20,682,678	—	31 Mar 2024	13F
DEUTSCHE BANK AG\	13F	Company	1.1%	667,297	$19,511,764	—	31 Mar 2024	13F
GW&K Investment Management, LLC	13F	Company	1.1%	649,385	$18,988,000	—	31 Mar 2024	13F
NORTHERN TRUST CORP	13F	Company	0.99%	590,493	$17,266,015	—	31 Mar 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.91%	539,582	$15,777,378	—	31 Mar 2024	13F
Frazier Life Sciences Management, L.P.	13F	Company	0.88%	523,166	$15,297,374	—	31 Mar 2024	13F
Caligan Partners LP	13F	Company	0.82%	484,711	$14,172,950	—	31 Mar 2024	13F
Assenagon Asset Management S.A.	13F	Company	0.77%	454,801	$13,298,381	—	31 Mar 2024	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.74%	440,232	$12,872,384	—	31 Mar 2024	13F
Hudson Bay Capital Management LP	13F	Company	0.69%	407,500	$11,915,300	—	31 Mar 2024	13F
Paradigm Biocapital Advisors LP	13F	Company	0.67%	400,000	$11,696,000	—	31 Mar 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.64%	381,733	$11,161,873	—	31 Mar 2024	13F
Laurion Capital Management LP	13F	Company	0.61%	364,762	$10,665,641	—	31 Mar 2024	13F
D. E. Shaw & Co., Inc.	13F	Company	0.61%	362,134	$10,588,798	—	31 Mar 2024	13F
David P. Schenkein	3/4/5	Director	— mixed-class rows	219,218 mixed-class rows	$10,131,565	—	20 Jun 2024	3/4/5
Eagle Health Investments LP	13F	Company	0.56%	330,830	$9,673,469	—	31 Mar 2024	13F
Vestal Point Capital, LP	13F	Company	0.55%	325,000	$9,503,000	—	31 Mar 2024	13F
Cutter Capital Management, LP	13F	Company	0.49%	288,580	$8,438,079	—	31 Mar 2024	13F
MARSHALL WACE, LLP	13F	Company	0.47%	277,996	$8,128,603	—	31 Mar 2024	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.45%	268,979	$7,864,946	—	31 Mar 2024	13F
NORDEA INVESTMENT MANAGEMENT AB	13F	Company	0.45%	266,588	$7,824,358	—	31 Mar 2024	13F
AXA S.A.	13F	Company	0.45%	265,373	$7,759,507	—	31 Mar 2024	13F
NORGES BANK	13F	Company	0.44%	262,457	$7,674,243	—	31 Mar 2024	13F
Rafferty Asset Management, LLC	13F	Company	0.37%	221,209	$6,468,151	—	31 Mar 2024	13F
Bank of New York Mellon Corp	13F	Company	0.33%	195,958	$5,729,810	—	31 Mar 2024	13F
CITIGROUP INC	13F	Company	0.33%	194,480	$5,686,595	—	31 Mar 2024	13F
PRUDENTIAL FINANCIAL INC	13F	Company	0.33%	194,132	$5,676,420	—	31 Mar 2024	13F
UBS Group AG	13F	Company	0.29%	170,885	$4,996,677	—	31 Mar 2024	13F
Gamma As Sector	13F	Individual	0.28%	164,378	$4,806,413	—	31 Mar 2024	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.27%	159,288	$4,657,581	—	31 Mar 2024	13F
TD ASSET MANAGEMENT INC	13F	Company	0.26%	156,418	$4,573,662	—	31 Mar 2024	13F

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (AGIO) as of Q2 2024

As of 30 Jun 2024, AGIOS PHARMACEUTICALS, INC. - Common Stock, Par Value $0.001 per share (AGIO) was held by 203 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 58,132,966 shares. The largest 10 holders included FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock Inc., Bellevue Group AG, PRICE T ROWE ASSOCIATES INC /MD/, Erste Asset Management GmbH, DIMENSIONAL FUND ADVISORS LP, STATE STREET CORP, ARMISTICE CAPITAL, LLC, and JPMORGAN CHASE & CO. This page lists 203 institutional shareholders reporting positions in this security for the Q2 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders

183

Q2 2024 holders

203

Holder diff

Investor	Q1 2024 Shares	Q2 2024 Shares	Share Diff	Share Chg %	Q1 2024 Value $	Q2 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.